Pfizer develops new hemophilia treatment by inhibiting clot breakdown
Pfizer is exploring a novel strategy for treating hemophilia, aiming to inhibit the body's natural mechanisms for dissolving blood clots rather than replacing missing clotting factors.
Pfizer Inc. is developing a new approach to treating hemophilia, a rare genetic bleeding disorder. Instead of replenishing the body's deficient clotting factors, the company's researchers are focusing on inhibiting the body's natural processes that dissolve blood clots.
Traditionally, hemophilia treatment has involved patients receiving intravenous infusions of clotting factors to prevent or treat bleeding. This method can be burdensome, often requiring multiple infusions per week, totaling up to 150 annually, and is particularly challenging for children.
Pfizer's novel strategy targets tissue factor pathway inhibitor (TFPI), a natural anticoagulant protein that inhibits clot formation. By developing a monoclonal antibody against TFPI, Pfizer aims to block its activity. This treatment is anticipated to offer greater convenience through potential self-administration via injection.
In addition to this program, Pfizer is also advancing two gene therapy programs for hemophilia. The company's broad objective is to create diverse therapeutic options to meet the varied needs of patients with hemophilia.